Diana Clarke, PhD is an Assistant Professor of Pediatrics in Infectious Diseases at the Boston University School of Medicine. She originally earned a doctorate of pharmacy and worked as an assistant professor as well as a clinical pharmacist before adjuncting as an instructor of pediatrics at the Boston University School of Medicine for one year. After 26 years of working in the industry, she was hired as an Assistant Professor at BUSM, but still continues to work as a research pharmacist at BMC. Her commitment to pediatrics is demonstrated through her 12 year membership to the WHO Pediatric Antiretroviral Working Group and her past experience as the Vice Chair of the Pharmacy Resource Committee in the International Maternal Pediatric-Adolescent AIDS Clinical Trials Network Group.
- State University of New York at Buffalo, PharmD
- University of Rhode Island College of Pharmacy, BS
- Published on 5/1/2020
Clarke DF, Acosta EP, Cababasay M, Wang J, Chain A, Teppler H, Popson S, Graham B, Smith B, Hazra R, Calabrese K, Bryson Y, Spector SA, Lommerse J, Mirochnick M. Raltegravir (RAL) in Neonates: Dosing, Pharmacokinetics (PK), and Safety in HIV-1-Exposed Neonates at Risk of Infection (IMPAACT P1110). J Acquir Immune Defic Syndr. 2020 May 01; 84(1):70-77. PMID: 31913995.
- Published on 4/29/2020
Epstein RL, Penwill N, Clarke DF, Hamilton S, Horbowicz K, Dorfman D, Moses JM, Cooper ER. "Meds-in-Hand" Intervention to Reduce Critical Process Delays in Pediatric Human Immunodeficiency Virus Post-Exposure Prophylaxis. J Pediatric Infect Dis Soc. 2020 Apr 29. PMID: 32347312.
- Published on 12/1/2019
Clarke DF, Mirochnick M, Acosta EP, Capparelli E, Chain A, Teppler H, Smith B, Lommerse J. Use of Modeling and Simulations to Determine Raltegravir Dosing in Neonates: A Model for Safely and Efficiently Determining Appropriate Neonatal Dosing Regimens: IMPAACT P1110. J Acquir Immune Defic Syndr. 2019 12 01; 82(4):392-398. PMID: 31658182.
- Published on 9/1/2018
Schreiner CN, Ahlfors CE, Wong RJ, Stevenson DK, Clarke DF, Mirochnick M. In Vitro Study on the Effect of Maraviroc or Dolutegravir on Bilirubin to Albumin Binding. Pediatr Infect Dis J. 2018 09; 37(9):908-909. PMID: 29561509.
- Published on 11/8/2017
Clarke DF, Penazzato M, Capparelli E, Cressey TR, Siberry G, Sugandhi N, Mirochnick M. Prevention and treatment of HIV infection in neonates: evidence base for existing WHO dosing recommendations and implementation considerations. Expert Rev Clin Pharmacol. 2018 Jan; 11(1):83-93. PMID: 29039686.
- Published on 1/1/2017
Clarke DF, Yildirim I, Cooper ER. Rapid Initiation of Antiretrovirals in Two Newly Diagnosed HIV-infected Infants. Pediatr Infect Dis J. 2017 Jan; 36(1):61-62. PMID: 27749654.
- Published on 11/1/2014
Clarke DF, Acosta EP, Rizk ML, Bryson YJ, Spector SA, Mofenson LM, Handelsman E, Teppler H, Welebob C, Persaud D, Cababasay MP, Wang J, Mirochnick M. Raltegravir pharmacokinetics in neonates following maternal dosing. J Acquir Immune Defic Syndr. 2014 Nov 1; 67(3):310-5. PMID: 25162819.
- Published on 9/1/2013
Clarke DF, Wong RJ, Wenning L, Stevenson DK, Mirochnick M. Raltegravir in vitro effect on bilirubin binding. Pediatr Infect Dis J. 2013 Sep; 32(9):978-80. PMID: 23470680.
- Published on 2/23/2011
Mirochnick M, Clarke D. Oseltamivir pharmacokinetics in pregnancy: a commentary. Am J Obstet Gynecol. 2011 Jun; 204(6 Suppl 1):S94-5. PMID: 21640232.
- Published on 12/1/2010
Mirochnick M, Best BM, Clarke DF. Antiretroviral pharmacology: special issues regarding pregnant women and neonates. Clin Perinatol. 2010 Dec; 37(4):907-27, xi. PMID: 21078458.
View 3 more publications: View full profile at BUMC